Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the use of Platelet Rich Plasma therapy for skin rejuvenation and hair loss and reports no new clinical results, noting its minimally invasive nature and effect on skin texture and elasticity.

This article discusses the popularity and mechanisms of Platelet Rich Plasma therapy for skin rejuvenation and hair loss, but it reports no new clinical results.

This review evaluates the clinical efficacy of platelet-rich plasma therapy in dermatology, highlighting recent research findings and discussing its potential and limitations without reporting new clinical results.

This review discusses PRP therapy's history, mechanisms, and innovations in its use across various medical fields, but provides no new clinical results; the authors highlight challenges like standardization and regulatory issues.

This study found that high leukocyte platelet-rich plasma was more effective in increasing hair density and patient satisfaction for androgenetic alopecia treatment.

This study found that in a testosterone-induced androgenetic alopecia mouse model, the combination of PRP-derived small extracellular vesicles and 5% minoxidil significantly improved hair follicle density and the anagen-to-telogen ratio compared to minoxidil alone, suggesting a synergistic effect that enhances hair growth.

This study found that both buffy coat and apheresis PRP are effective for treating androgenetic alopecia, with buffy coat PRP associated with higher patient-reported improvement despite lower platelet counts.

This review discusses the potential and current limitations of regenerative therapies like PRP and stem cells in dermatology, highlighting the need for more clinical trials to standardize protocols and optimize outcomes.

In this study, PRP combined with systemic therapy for androgenetic alopecia showed higher, but not statistically significant, improvements in hair density and width compared to PRP alone, with no increase in side effects; further prospective studies are recommended.

This study found that androgenetic alopecia patients treated with a combination of PRP and systemic therapy experienced greater but non-significant improvements in hair density and width compared to PRP monotherapy, without additional adverse effects, suggesting potential benefits for further exploration of combination regimens.

This study found that combining platelet-rich plasma with systemic therapies for androgenetic alopecia may result in greater improvements in hair density and width than using PRP alone, though the differences were not statistically significant.

This study found that local heterologous leukocyte-rich platelet-rich plasma improved distal skin flap viability in rats by reducing necrosis compared to the control group.

This study found that while both buffy coat and apheresis PRP improved androgenetic alopecia, the buffy coat method was linked to greater patient-reported improvement despite having lower platelet counts.

This study concluded that Growth Factor Concentrate was more effective than Platelet-Rich Plasma in enhancing hair growth and patient satisfaction for individuals with androgenic alopecia and telogen effluvium, while maintaining similar safety.

This study concluded that in female pattern hair loss patients, CGF and i-PRF treatments were more effective than PRP in increasing target area hair count, with i-PRF having the lowest adverse event rate.

In this study, researchers using visual analysis reported a rising trend in platelet-rich plasma research from 2020 to 2024, with significant contributions from the United States and China, highlighting key applications in orthopedics, tissue engineering, and potential future focuses in neurogenic pain and regenerative medicine.

This study concluded that platelet-rich plasma therapy was as effective as intralesional triamcinolone acetonide in treating localized alopecia areata on the scalp.

This review explores the potential links between PRP treatments for hair loss and scalp skin cancer risk, finding current evidence supports PRP's safety but emphasizes the need for further studies and routine monitoring.

This study used a probabilistic framework to show that platelet-rich plasma preparation results in significant variability in platelet dose due to factors like injected volume and concentration factor.

In this study, baseline neutrophil-to-lymphocyte ratio (NLR) was associated with predicting early trichoscopic response in patients undergoing PRP-based treatment for non-scarring alopecia.

This review discusses the potential of cold atmospheric plasma as a selective antitumor therapy for breast cancer but reports no clinical results, emphasizing its promise and the challenges to its use in precision oncology.

This study found that exosome therapy led to significantly better hair regrowth and patient satisfaction than platelet-rich plasma in men with androgenetic alopecia.

This review discusses platelet-rich plasma therapy for androgenic alopecia and reports no clinical results; the authors emphasize the need for standardized protocols and large-scale studies to confirm its long-term efficacy.

This systematic literature review found that exosome and PRP therapies show promise as effective, minimally invasive options for treating androgenetic alopecia, with clinical benefits potentially superior to or complementary to minoxidil, although standardization and larger clinical trials are needed to confirm long-term safety and efficacy.

This review summarizes current clinical evidence on platelet-rich plasma, highlighting its effectiveness in treating androgenetic alopecia and as an adjunctive therapy for acne scars, while noting challenges in standardizing preparation techniques.

This study suggests that platelet-rich plasma may provide short-term improvement in hair density for female pattern hair loss, but results varied and more rigorous trials are needed to establish optimal protocols.

This study found that platelet-rich plasma significantly accelerated wound healing in the donor area after follicular unit excision for hair transplantation in men.

This study identified CD28 as a promising drug target for treating alopecia areata, using a multi-omics approach to highlight its role in immune regulation and linking it to favorable safety profiles, thus offering a strategy for autoimmune target discovery.

This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.